
CLAIMS


1. A RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, for use in treating a patient with $Her2^+$ cancer, wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic agent.


2. A RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, and a Her2-targeted therapeutic agent for use in combination in treating a patient with $Her2^+$ cancer.

3. A Her2-targeted therapeutic agent for treating $Her2^+$ cancer in a patient with $Her2^+$ cancer, with a therapeutic response less than a complete response to treatment with a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof,

in combination with the RXR agonist.

4. A RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, for treating $Her2^+$ cancer in a patient with $Her2^+$ cancer, with a therapeutic response less than a complete response to treatment with a Her2-targeted therapeutic agent,

in combination with the Her2-targeted therapeutic agent.


5. The RXR agonist of any one of claims 1-4, wherein thyroid hormone is administered in conjunction with the RXR agonist.

6. The RXR agonist of claim 5, wherein the thyroid hormone is thyroxine.

7. The RXR agonist of any one of claims 1-6, wherein the RXR agonist is a compound of Formula I.

8. The RXR agonist of any one of claims 1-6, wherein the RXR agonist is pharmaceutically-acceptable salt of a compound of Formula I.

9. The RXR agonist of any one of claims 1-6, wherein the RXR agonist is a compound of Formula II



(Formula II).

10. The Her2-targeted therapeutic agent of any one of claims 1-9 comprising an anti-Her2 therapeutic antibody.

11. The Her2-targeted therapeutic agent of claim 10, wherein the therapeutic antibody is trastuzumab or pertuzumab.

12. The Her2-targeted therapeutic agent of any one of claims 1-9, comprising an antibody-drug conjugate wherein the antibody is an anti-Her2 antibody.

13. The Her2-targeted therapeutic agent of claim 12, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.


14. The Her2-targeted therapeutic agent of any one of claims 1-9, comprising a Her2 kinase inhibitor.

15. The Her2-targeted therapeutic agent of claim 14, wherein the Her2 kinase inhibitor is lapatinib or neratinib.

16. The RXR agonist and/or Her2-targeted therapeutic agent of any one of claims 1-15, wherein the $Her2^+$ cancer is $Her2^+$ breast cancer.

17. The RXR agonist and/or Her2-targeted therapeutic agent of any one of claims 1-15, wherein the $Her2^+$ cancer is $Her2^+$ gastroesophageal cancer, ovarian cancer, stomach cancer, adenocarcinoma of the lung, uterine cancer, serous endometrial carcinoma, or salivary duct carcinoma.

18. A combination comprising a Her2-targeted therapeutic agent and a RXR agonist of Formula I,




(Formula I)

19. wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof.

20. The combination of claim 18, further comprising thyroid hormone.

21. The combination of claim 18, wherein the RXR agonist is a compound of Formula II



(Formula II).

22. The combination of claim 18, wherein the Her2-targeted therapeutic agent

comprises an anti-Her2 therapeutic antibody.

23. The combination of claim 22, wherein the therapeutic antibody is trastuzumab or pertuzumab.

24. The combination of claim 18, wherein the Her2-targeted therapeutic agent comprises an antibody-drug conjugate wherein the antibody is an anti-Her2 antibody.

25. The combination of claim 24, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.

26. The combination of claim 18, wherein the Her2-targeted therapeutic agent comprises a Her2 kinase inhibitor.

27. The combination of claim 26, wherein the Her2 kinase inhibitor is lapatinib or neratinib.